TABLE I.
Patient Characteristics
| Patient Characteristics | Prevention | Treatment | Total |
|---|---|---|---|
| Number | 20 | 20 | 41 |
| Median Age (range), in yrs. | 9.1 (2.5 – 22.4) | 14.1 (3.3 – 20.4) | 11.33 (2.52 - 22.4) |
| Male Gender (%) | 12 (60%) | 9 (45%) | 21 (52%) |
| Ethnic/Race background | |||
| Hispanic | 910 (50%) | 10 (52%) | 22 (52%) |
| Caucasian/White | 6 (30%) | 6 (28%) | 12 (29%) |
| Asian/Pacific Islander/AfAm | 4 (20%) | 4(20%) | 8 (19%) |
| Preparative Regimen | |||
| TBI based | 13 | 14 | 27 |
| FLU/MEL | 5 | 4 | 9 |
| BU/CY | 1 | 1 | 2 |
| Other | 1 | 1 | 2 |
| Dx | |||
| ALL | 7 | 10 | 17 |
| AML | 4 | 7 | 11 |
| SAA | 2 | 2 | 4 |
| Fanconi’s | 2 | 2 | |
| Lymphoma | 3 | 3 | |
| Other | 2 | 2 | 4 |
| Cell Source | |||
| HLA identical sibling | 8 | 4 | 12 |
| Unrelated cord | 6 | 3 | 9 |
| MUD | 6 | 14 | 20 |
| GVHD prophylaxis | |||
| TAC/SIR | 20 | 1 | 21 |
| TAC/MTX | 11 | 11 | |
| CSA/MTX | 5 | 5 | |
| TAC/MMF or CSA/MMF | 4 | 4 |
AfAm-African-American; TBI-total body irradiation; FLU/MEL –fludarabine/melphalan; BU/CY-busulfan/cyclophosphamide; ALL-acute lymphoblastic leukemia; AML-acute myelogenous leukemia; SAA-severe aplastic anemia; MUD-matched unrelated donor; GVHD-graft-vs-host disease; TAC-tacrolimus; SIR-sirolimus; CSA-cyclosporine; MTX-methotrexate; MMF-mycophenolate mofetil